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A B S T R A C T
Novel nanomaterials and advanced nanotechnologies prompt the fast development of new
protocols for biomedical application. The unique light-to-heat conversion property of na-
noscale materials can be utilized to produce novel and effective therapeutics for cancer
treatment. In particular, near-infrared (NIR) photothermal therapy (PTT) has gained popu-
larity and very quickly developed in recent years due to minimally invasive treatments for
patients. This review summarizes the current state-of-the-art in the development of inor-
ganic nanocomposites for photothermal cancer therapy. The current states of the design,
synthesis, the cellular uptake behavior, the cellular cytotoxicity and both in vivo and in vitro
nanoparticle assisted photothermal treatments of inorganic photothermal therapy agents
(PTA) are described. Finally, the perspective and challenges of PTT development are pre-
sented and some proposals are suggested for its further development and exploration.This
summary should provide improved understanding of cancer treatment with photother-
mal nanomaterials and push nanoscience and nanotechnology one step at a time toward
clinical applications.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-








Directly or indirectly, cancer affects most people’s lives. Cancer
is one of the leading causes of death and accounted for 8.2
million deaths worldwide in 2012 [1] and the incidence rate
is increasing year by year. The main reason for this dismal
picture is that even with the current state of the art of cancer
diagnosis, usually this disease is detected in an advanced stage,
when the primary tumor has metastasized and invaded other
organs, which is beyond surgical intervention. In addition,
current chemo- and radiation therapies have many well-
known disadvantages, including relatively poor specificity
toward malignant tissues, systemic side effects, low efficacy
and drug resistance [2]. Therefore, to advance cancer therapy,
therapeutic methods that should selectively eliminate only dis-
eased cells/tissues without causing collateral damage will be
expected.
As a promising alternative or supplement to conventional
cancer treating approaches, photothermal therapy (PTT) has
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caused considerable attention because of its advantages in-
cluding minimal invasion, few complications, and rapid
recovery. PTT, also known as photothermal ablation or optical
hyperthermia, employing photo-absorbers and near-infrared
light energy sources, provides a precise and minimally inva-
sive alternative for cancer treatment [3,4]. It is a procedure based
on localized heating due to light absorption for selective de-
struction of abnormal cells.To enhance anti-cancer efficacy and
optimize therapy, integration of multiple treatment strate-
gies with synergistic effects is highly expected [5]. Among these
treatment strategies, the combination of PTT with chemo-
therapy, termed chemo-photothermal therapy, as a minimally
invasive, controllable, and highly efficient treatment method,
has drawnwidespread attention [6,7]. In PTT, near-infrared (NIR)
light (650–900 nm) is preferred for such an application because
of its easy operation, its ability to be locally focused on a spe-
cific region, and its minimal absorbance by skin and tissues
to allow for noninvasive penetration of reasonably deep tissues
[8]. The key component of this technique is a photothermal
transducer that can efficiently absorb and convert NIR light into
heat through a non-radiative mechanism.
Over the past decade, many different types of photother-
mal therapy agents (PTA) have been reported, including organic
compounds or materials (e.g., indocyanine green [9,10] and
polyaniline [11]) and inorganic nanomaterials (e.g., noble metal
nanoparticles [12,13], metal chalcogenide [14,15], and carbon-
based materials [16–19]).When combined with NIR light, all of
them are able to generate sufficient heat to raise the local tem-
perature and thus kill cancer cells. Organic photothermal
therapy has good biocompatibility and biodegradability, and
therefore can be used for nanobiotechnology. However, the low
photothermal conversion efficiency, poor photothermal sta-
bility and complicated synthesis process of thesematerials limit
their application for PTT. As an alternative, inorganic PTA have
received great interest in recent years, because of their high
photothermal conversion efficiency and the ease of synthe-
sis and modification; for example, the inorganic nanoparticle
size, shape and surface properties can be facilely controlled.
In the past decade, near-infrared light-responsive inor-
ganic nanomaterials, such as gold nanoparticles, carbon
nanotubes, and copper sulfide nanoparticles (Fig. 1) effi-
ciently convert optical energy into thermal energy and enhance
the efficacy of photothermal ablation therapy. Some applica-
tions are under clinical trials. In this review, we summarize the
recent advances in the structural and functional evolution of
inorganic nanomaterials employed in PTT. These recent pro-
gresses in materials design will lead to deeper insight of the
chemistry and photonic as well as to promote the develop-
ment of PTT into practical applications.The aim of this review
is to arouse more attention toward inorganic photothermal
nanomaterials used in cancer therapy and to encourage future
work to push forward the advancement of this biomedical area.
2. Various inorganic nanomaterials for PTT
For biomedical applications, inorganic nanomaterials, including
Au-based nanomaterials, Pd nanoparticles, CuS nanoparticles,
graphene, and carbon nanotubes etc., have attracted much
attention in PTT. This article summarizes recent progress on
various inorganic photothermal nanomaterials, including the
background, synthesis,modification, cytotoxicity as well as their
applications in biomedicine.
2.1. Colloidal noble metal nanoparticles
Noble metal nanoparticles, especially for Au and Pd
nanoparticles, have been proven to show strong scattering and
absorption of light in visible and near-infrared region owing
to their localized surface plasmon resonances. The absorbed
light is then turned into thermal energy.With pulsed light ir-
radiation, transient thermal power generated in nanoparticles
introduces abundant thermodynamic effects, such as abla-
tion, ultrafast heating, thermal expansion, surface melting, and
reshaping.
2.1.1. Gold nanoparticles
Localized surface plasmon resonance of gold nanocrystals
endows them the capability to strongly absorb and/or scatter
light at synthetically controllable resonance wavelengths, which
is the underlying reason for their many applications [20–23].
A wide variety of Au nanostructures, including aggregates of
colloidal particles, nanoshells, nanocages, nanorods and
nanocrosses have been demonstrated for cancer photother-
mal therapy with NIR light. In the case of spherical gold
nanoparticles, the absorptionmaximum exists between 400 and
600 nm. Therefore, in in vivo applications, very low light pen-
etration and thus inefficient photothermal heating is generated
[24]. In contrast, gold nanorods (GNRs) have attracted much in-
terest because the absorption range of light can be finely tuned
by adjusting the aspect ratio, so the heating efficiency can be
maximized by using ~800 nm absorption maximum.Also, they
Fig. 1 – Various types of inorganic nanocomposite
materials for photothermal therapy for cancer.
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have the advantages of efficient large-scale synthesis, easy
functionalization, and colloidal stability [25,26]. However the
clinical application of GNRs was limited due to a slight cyto-
toxicity caused by the remaining excess cetyltrimethyl-
ammonium bromide (CTAB), which is used as a template during
synthesis and envelops the surfaces of the GNRs [27,28].To dis-
tinguish between the toxicity of the GNRs core and the exterior
ligands, Zhu et al. [29] systematically evaluated the cellular
uptake behavior and cytotoxicity of Au nanorods with various
surface coatings, including organic cetyltrimethylammonium
bromide (CTAB), poly(sodium 4-styrenesulfonate) (PSS), and
poly(ethylene glycol) (PEG), and inorganic mesoporous silica
(m-SiO2), dense silica (d-SiO2), and titanium dioxide (TiO2). The
cellular behavior of Au nanorods was found to be highly
dependent on the surface coating. CTAB-, PSS-, and m-SiO2-
coated Au nanorods exhibit notable cytotoxicity, while PEG-,
d-SiO2-, andTiO2-coated Au nanorods do not induce cell injury.
Thus, the surface modifications of GNRs shall reduce the cy-
totoxic effect. For example, phosphatidylcholine (PC)-modified
nanorods [30], poly(4-styrenesulfonic acid) (PSS)-coated
nanorods [31], GNR-embedded polymeric nanoparticles [32], and
PEG-modified nanorods [33] have shown cytotoxicities lower
than that of the CTAB-capped nanorods themselves and good
photothermal effects.
Although ligand-conjugated GNRs are effective for photo-
thermal killing of cancer cells in vitro, desirable photothermal
therapeutic effects in an in vivo animal model are limited due
to a high liver uptake during circulation [34]. A high-level lo-
calization in the liver of CTAB-stabilized GNRs at 0.5 h after
intravenous injection, which might be associated with the hard
and rigid characteristics of GNRs, was reported [35]. To over-
come the limited effect of GNRs on in vivo cancer photothermal
therapy, PEGylation modified GNRs attempted to lower the
cytotoxicity and the liver accumulation of GNRs. However, com-
plete suppression of tumor growth when using a hyperthermia-
based treatment was not achieved, probably due to the very
fast excretion of the PEGylated GNRs from the body (half-life
of ~1 h).Thus, a new biocompatible vehicle for the efficient de-
livery of GNRs into tumor sites is still an unmet need for safe
and effective cancer therapy based on GNRs. In addition,
specific targeting therapy of GNRs also is another key issue for
efficient cancer photothermal therapy. The biological modifi-
cation of Au nanoparticles can be achieved on their surfaces,
which is beneficial to improve biological activity and provide
targeting property. For example, Aptamer-conjugated nanorods
[36], folate-conjugated nanorods [37], and RGD-conjugated
dendrimer modified nanorods [38] have demonstrated selec-
tive and efficient photothermal killing of targeted tumor cells.
Choi et al. [39] developed photo-cross-linked, Pluronic-based,
temperature-sensitive nanocarriers that possessed excellent
reservoir characteristics and a simple loadingmethod with high
loading capacity for large molecules (e.g., proteins and gold
nanoparticles). Importantly, these nanocarriers showed a long
circulation time, a good tumor accumulation, and low liver
uptake, which were associated with the flexible and soft char-
acteristics as well as the hydrophilic surface from the PEG part
of Pluronic. Furthermore, the tumor targeting and prolonged
circulation (up to 72 h) were significantly improved and could
be optimized by chitosan conjugation.The GNR-loaded, Pluronic-
based nanocarriers as a hyperthermia agent were applied for
enhanced cancer photothermal therapy. The GNR-loaded
nanocarriers showed serum stability and photothermolysis of
cancer cells in vitro.The GNR concentration and the laser power
density required for photodestruction of cancer cells were also
significantly reduced, compared to other formulations, by using
the nanocarrier system. Most of all, the optimized GNR-
loaded nanocarriers resulted in a very impressive therapeutic
effect in vivo in nude mice bearing tumors, and complete re-
sorption of the tumor was achieved (Fig. 2). As a theranostic
platform, GNRs bear two disadvantages: (1) a relatively low spe-
cific surface area limits the loading amount of drugs, and due
to the often-observed clustering and aggregating of the GNRs
within cells; (2) when GNRs were exposed to NIR laser, the de-
sirable NIR window shifts to the visible spectral region and the
advantage of deep tissue penetration is lost.To overcome these
two drawbacks of GNRs, Zhang et al. [40] developedmesoporous
silica-coated gold nanorods (Au@SiO2) as a novel cancer
theranostic platform.The large specific surface area of meso-
porous silica guarantees a high drug payload. More interest-
ingly,Au@SiO2 as a drug carrier, under laser irradiation the drug
Fig. 2 – (a) Schematic illustration of the preparation of the pluronic-based nanocarriers and GNR loading into the
nanocarriers. (b) Change in tumor volumes (an enlarged graph at initial time) and (c) the tumor images after NIR laser
irradiations at 24 and 48 h after single i.v. injection of the nanomaterials. Reproduced with permission from Reference [39].
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release rate becomes much faster for any pH because the laser-
converted heat dissociates the strong interactions between
doxorubicin (DOX) and silica, thus more DOXmolecules are re-
leased. The incorporation of the two nanomaterials created a
new functionality: NIR laser-controlled drug release. For the goal
of on-demand therapy and personalized medicine, the thera-
peutic modes of Au@SiO2-DOX, either chemotherapy or
hyperthermia, can be manipulated simply by changing laser
power density.
PTT has been demonstrated with certain types of Au
nanostructures in early clinical trials.As an example, pilot clini-
cal studies with Au nanoshell (Au nanoshells about 150 nm in
diameter with a coating of polyethylene glycol 5000) have been
approved by the Food and Drug Administration (FDA), wherein
the nanoshells are given intravenously to patients for the treat-
ment of head and neck cancer, as well as primary and/or
metastatic lung tumors [41,42]. For practical application, lo-
cation and size of cancer shall be confirmed first before therapy.
Second, the treatment procedure needs to be monitored in real
time during therapy. Finally, the effectiveness has to be as-
sessed after therapy. Based on aforementioned claims, the
design and synthesis of new PTT agents with imaging are of
great importance. Ke et al. [43] developed a novel multifunc-
tional theranostic agent for ultrasound contrast imaging and
PTT. The gold-nanoshell microcapsules (GNS-MCs) were ob-
tained by electrostatic adsorption of gold nanoparticles as seeds
onto the polymeric microcapsule surfaces, followed by the for-
mation of gold nanoshells by using a surface seeding method.
Poly(lactic acid) (PLA), which is biodegradable and possesses
an ultrasound signaling capability, was used as polymeric mi-
crocapsule in this study. NH2OH·HCl was used to reduce the
gold precursor (HAuCl4) to bulk metal without the nucleation
of new particles. Subsequently, all the added gold precursor
was reduced and incorporated into larger particles that were
deposited on the surface of the capsules. Finally, the micro-
capsules were freeze-dried.The encapsulated water in the inner
aqueous phase of the microcapsules was sublimated to leave
a small hollow space that could provide a basis for the
ultrasound-responsive properties. In the in vivo ultrasound
imaging process, GNS-MCs were intravenously injected into
rabbits, pulse inversion harmonic imaging (PIHI) contrast mode
(with mechanical index, MI = 0.42) and conventional B-mode
sonograms before and after administration of GNS-MCs, as
shown in Fig. 3a and b. Excellent enhancements of rabbit kidney
images suggested that GNS-MCs were able to traverse pulmo-
nary capillaries to achieve systemic enhancement.The contrast
enhancement can last more than 5 minutes, which is long
enough to satisfy the clinical requirements.To evaluate the lo-
calized tumor photohyperthermic effect of GNS-MCs, HeLa cells
(human cervical carcinoma cell lines) cultured in six-well plates
were incubated with the GNS-MCs for 1 h, followed by illumi-
nation with an NIR laser (808 nm and 8 W/cm2 for 10 min).
Under an inverted fluorescence microscope (Fig. 3c–f), a dark
region was observed in the presence of both the agent and the
laser (Fig. 3f) that arises from the NIR laser-induced hyper-
thermic effect on cancer cells. In contrast, exposure of cancer
cells to either GNS-MCs or a high-intensity NIR laser alone did
not compromise cell viability (Fig. 3c–e), thus indicating that
GNS-MCs will cause cancer cells to die through photother-
mal effect only under NIR laser irradiation.
At the next step in the development of Au nanoshells, a
novel multifunctional drug-delivery platform is developed based
on cholesteryl succinyl silane (CSS) nanomicelles loaded with
doxorubicin, Fe3O4 magnetic nanoparticles, and gold nanoshells
(CSS-DOX-Fe3O4-Au-shell nanomicelles), which can combine
magnetic resonance (MR) imaging, magnetic-targeted drug
delivery, light-triggered drug release, and PTT into one
nanomaterial [44]. The synthesis of the CSS-DOX-Fe3O4-Au-
shell nanomicelles was a multistep procedure. Especially, an
enhancement for T2-weighted MR imaging is observed for the
CSS-DOX-Fe3O4-Au-shell nanomicelles compared with that of
sodium citrate modified Fe3O4 nanoparticles. In addition, the
samples were irradiated repeatedly over a period of 10 min, fol-
lowed by 1 h intervals with the laser turned off. A rapid release
was observed upon NIR irradiation and the DOX release rate
slowed down when the NIR irradiation was switched off. After
the first NIR exposure for 10 min, the percentage of released
DOX increased from 7.1% to 18.4%. The percentage increased
to 19.7% over the whole period without NIR laser irradiation,
significantly lower than that with NIR laser irradiation (39.5%).
This research achieved a synergistic effect in killing cancer cells
by combined photothermal therapy and the magnetic-field-
guided drug delivery.
Recently, the branched or star-shaped Au nanostructures
consisting of a core and protruding arms have received par-
ticular interest due to their unique morphology and optical
properties [45,46]. Owing to the presence of sharp tips as well
as their high surface to volume ratios, branched Au nano-
structures could be more effective in photothermal conver-
sion and drug loading relative to those with smooth surfaces
[47]. Wang et al. [48] prepared the Au nanohexapods, consist-
ing of an octahedral core and six arms grown on its six vertices,
by reducing HAuCl4 with DMF in an aqueous solution contain-
ing Au octahedral seeds (Fig. 4a). By controlling the length of
the arms, their localized surface plasmon resonance (SPR) peaks
could be tuned from the visible to the near-infrared region for
deep penetration of light into soft tissues.When compared with
the PEGylated nanorods (53.0 ± 0.5 °C) and nanocages
(48.7 ± 3.5 °C), PEGylated nanohexapods showed the highest
(55.7 ± 2.4 °C) photothermal conversion efficiency in vivo, owing
to their highest tumor uptake and photothermal conversion
efficiency per Au atom. The different result using Au
nanohexapods, nanorods, and nanocages indicates that all these
Au nanostructures could absorb and convert NIR light into heat
(Fig. 4b).Au nanohexapods exhibited the highest cellular uptake
and the lowest cytotoxicity in vitro for both the as-prepared and
the PEGylated samples. Combined together, Au nanohexapods
are promising candidates for cancer theranostics in terms of
both photothermal destruction and contrast-enhanced
diagnosis.
2.1.2. Palladium nanoparticles
A wide variety of anisotropic gold nanostructures, including
aggregates of colloidal particles, nanorods, nanoshells,
nanocrosses, have been demonstrated for cancer photother-
mal therapy with NIR light. However, studies have shown that
many anisotropic gold nanostructures exhibiting NIR SPR lack
good photothermal stability upon irradiation with high-
power NIR lasers. The heat generated by NIR irradiation can
melt the anisotropic gold nanostructures into solid particles,
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leading to the loss of their NIR SPR [49,50]. To overcome this
limit, other noble nanoparticles with tunable localized surface
plasmon resonance in NIR region have been designed and syn-
thesized. Especially, palladium, because of its significantly higher
bulk melting point (MPPd = 1.828 K versusMPAu = 1.337 K), should
show enhanced photothermal stability. Using this point, Huang
et al. [13] prepared ultrathin hexagonal palladium nanosheets
with tunable (826–1068 nm) and strong SPR absorption (ex-
tinction coefficient, 4.1 × 109 M−1 cm−1) in the NIR region using
a general CO-confined growth method. The nanosheet edge
length is synthetically controllable from 20 to 160 nm, leading
to tunable NIR SPR. Unlike anisotropic gold nanorods, the two
dimensional structure of the palladium nanosheets appears
to be highly stable upon NIR irradiation. Upon irradiation for
30 min by a NIR laser (808 nm, 2 W), the sheet-like structure
of the palladium nanosheets was retained well leading to a good
SPR response in the NIR region, whereas gold nanorods were
severely distorted under a similar irradiation power. Further-
more, the as-prepared palladium nanosheets appear to be
Fig. 3 – In vivo ultrasonograms in the rabbit right kidney (a) pre- and (b) post administration of GNS-MCs. Both PIHI
(MI = 0.42) and conventional B-mode images are shown. (c–f) Fluorescence microscopy images of HeLa cells with different
treatments stained with calcein AM; (c) no agent and no laser irradiation; (d) laser irradiation only; (e) agent only; (f) with
both agent and laser irradiation. Note that the dark area represents the region of killed HeLa cells. (Scale bars: 500 mm;
GNS-MCs agent concentration: 0.3 mg/ml; NIR laser: 808 nm, 8 W/cm2, 10 min.) Reproduced with permission from
Reference [43].
Fig. 4 – (a) TEM images of the Au nanohexapods.
(b) 18F-FDG PET/CT co-registered images of mice
intravenously administrated with aqueous suspensions of
PEGylated nanohexapods. Tumors were treated either with
(solid circle + left arrow) or without (solid circle) laser
irradiation. Reproduced with permission from Reference
[48].
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largely biocompatible. The viable cell count for healthy liver
cells was reduced by only 20% after 48 h of exposure to a
600mg/mL solution of palladium nanosheets by incubating liver
cancer cells with polyethyleneimine-exchanged palladium
nanosheets. After 5 min of irradiation of an 808 nm laser with
a power of 1.4 W/cm2, ~100% of the cells were killed.This work
first suggests that Pd nanosheets have great potential in cancer
photothermal therapy.
In addition, the sizes of mentioned Au nanorods and
nanoshells are considerably large. For example, the size of Au
nanorods is typically of ~10 nm in diameter and ~50 nm in
length and Au nanoshells are more than 100 nm in diameter
[27,51,52]. A lot of investigations have demonstrated that the
optimum intravenously administered nanoparticles should be
between 10 and 50 nm in diameter to increase bloodstream cir-
culation time [53,54] because larger nanoparticles are removed
by the reticuloendothelial system (expressed as RES; e.g. liver,
spleen), and smaller particles are removed by the renal system
[55,56]. To overcome slow renal clearance and high, non-
specific accumulation in the reticuloendothelial system after
systematic administration in the applications of those
nanomaterials. Tang et al. [57] further successfully synthe-
sized the ultrasmall Pd nanosheets (SPNS) with an average
diameter of ~4.4 nm (Fig. 5), which is below the glomerular
filtration-size threshold (10 nm) and thus particularly inter-
esting for renal clearance studies. In addition, these SPNS were
surface functionalized with reduced glutathione (SPNS-GSH).
GSH (a tripeptide) can not only serve as capping agent to render
the nanoparticles with relatively low affinities to serum pro-
teins and lead to the desired stealthiness to the RES organs,
but also contribute to efficient renal clearance of small-sized
nanoparticles out of the body [58]. In Fig. 5d, the smaller sized
Pd nanosheets modified by GSH were both helpful in prolong-
ing their circulation and half-life in the blood. The circulation
half-lives was remarkably increased from 0.08 h for large Pd
nanosheets (LPNS) to 1.25 h for SPNS-GSH.Additionally, a higher
tumor accumulation was observed. Importantly, the total
amount of Pd in SPNS-GSH formulation was significantly low
in major organs, indicating that plenty of the SPNS-GSH were
rapidly excreted from the body within the first 24 h (Fig. 5e).
To minimize toxicity risks, an ideal nanomaterial-based therapy
agent should be effectively cleared out of the body after treat-
ment. The renal excretion has been recognized as a desirable
pathway for nanoparticle clearance. It was found that more
than 6.6% of the SPNS-GSHwere excreted out of the body within
1 day p.i. and up to 30.9% after 15 day p.i. (Fig. 5f). These ob-
servations confirm that SPNS-GSH could be cleared out from
the body through the renal excretion route into the urine. Sub-
sequently, they also developed a versatile system combining
chemotherapy with PTT for cancer therapy [59]. The system
is based on ultrasmall Pd nanosheets (SPNS) functionalized with
the anticancer drug doxorubicin hydrochloride (DOX) mainly
through Pd–N coordination bonding. SPNS have an average di-
ameter of ~4.4 nm. After the SPNS-DOX, hybrid nanoparticles
are surface-functionalized with reduced glutathione (GSH), the
obtained SPNS-DOX-GSH composite exhibits the following syn-
ergistic properties for cancer therapy: (1) The coordinative
loading of DOX on SPNS enhances its accumulation in tumor
tissue, which significantly reduces the laser power required to
achieve effective tumor ablation; (2) The DOXwas released from
Fig. 5 – (a) TEM image of ultra-small palladium nanosheets (SPNS). Inset: diameter distribution of the SPNS. (b) Absorption
spectrum of the SPNS. (c) Photothermal effect of SPNS. The temperature versus time plots was recorded for various
concentrations of SPNS upon irradiation by a 1 W laser. (d) SPNS-GSH showed prolonged blood circulation compared with
LPNS and SPNS. (e) Biodistribution of LPNS, SPNS and SPNS-GSH in various organs at 24 h p.i. Samples were measured
using ICP-MS. Error bars were based on the standard error of the mean of triplicate samples. (f) Urinary cumulative
excretion of SPNS-GSH in rats (n = 3) following i.v. administration at a single dose of 10 mg/kg. The amount of Pd in urinary
samples were measured by ICP-MS. Reproduced with permission from Reference [57].
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SPNS-DOX in a pH-responsive manner.The release rate of DOX
increased significantly with decreasing pH of buffer solu-
tions. The cancer cells usually have a lower pH than normal
cells.Thus SPNS-DOX should release DOX faster in cancer cells
than in normal cells; (3) The size of SPNS-DOX-GSH is below
the renal filtration size, allowing the therapeutic agents to be
effectively cleared from the body.
Besides the 2-dimensional Pd sheets, designed Pd nano-
particles also show very broad absorption through the UV–
Vis-NIR region. This broad absorption nature would help to
extend our choices on the wavelengths of NIR lasers in PTT
application. Recently, Xiao et al. prepared small Pd NPs with
a special porous architecture, which exhibit superior perfor-
mance in PTT compared with solid Pd nanocubes due to the
enhanced NIR absorption [60]. The photothermal conversion
efficiency of the porous Pd is as high as 93.4%, comparable to
typical gold nanorods. In the presence of porous Pd NPs (with
concentration as low as 23mg/mL), almost 100% HeLa cells were
destroyed after 4 min illumination with an 808 nm laser at a
power density of 8 W/cm2. Seventy percent of cells were killed
after 4 min irradiation with a 730 nm laser at power density
6W/cm2.These results demonstrated the high efficacy of porous
Pd nanoparticles for PTT. As the size of porous Pd NPs is rela-
tively small, it would prolong the blood circulation time when
it is administered to a live animal’s body. In particular, the
porous structure of Pd NPs may allow us to deliver the drug
into the cancer cell. This porous Pd structure holds great po-
tential in PTT and drug delivery.
2.2. Metal chalcogenide
Although the metallic nanoparticles (Au and Pd nanoparticles)
with bioinert properties show great promise for clinical ap-
plications, they are non-biodegradable, and their long-term
metabolism has raised concerns [61–63]. Based on reported
studies, semiconductor metal chalcogenide nanoparticles are
a class of inorganic photo absorbers that provide an alterna-
tive to noble metal nanoparticles. For clinical requirement,
before PTT application, cellular uptake and cytotoxicity prop-
erties of metal chalcogenide nanoparticles (MCNPs) have to be
investigated. Cellular uptake of CuS andWS and their good bio-
compatibility were confirmed with both healthy and cancer cell
lines. Several research groups have demonstrated that cell
uptake and cellular toxicity of MCNPs depend on the particle
size, shape, surface charge and functional groups [64,65]. No
cytotoxicity is observed up to 100 mg/mL for non-modified
100 nm MCNPs [66–69], which is far beyond the concentra-
tion required for most therapeutic treatments.
In contrast to exogenous gold, copper is essential for human
health [70]. In adults, the highest safe intake level of Cu is 10 mg
daily [71], indicating that CuS nanoparticles (CuS NPs) may be
metabolized by humans. CuS NPs with particle sizes of 35 and
11 nm [14,72], flower-like CuS superstructures (1 μm in diam-
eter) [73], and Cu9S5 plate-like nanocrystals (70 nm × 13 nm) [74]
have intense optical absorption at NIR region. However, criti-
cal pharmacological parameters such as body disposition and
long-term metabolism of these CuS nanostructures remain
unknown. Moreover, data regarding the cytotoxicity profile of
the CuS nanostructures are lacking. This knowledge is essen-
tial for clinical applications of CuS nanomaterials. Recently, Guo
et al. [75] compared degradability and toxicity between two types
of photothermal nanoparticles, i.e., hollow gold nanospheres
(HAuNSs) and hollow CuS nanoparticles (HCuSNPs), in mice
following systemic administration.The two nanoparticles were
formulated with similar particle size andmorphology.They were
both surface-modified with polyethylene glycol (PEG) to evade
uptake by monophagocytic systems. The injected PEGylated
HCuSNPs (PEG-HCuSNPs) are eliminated through both
hepatobiliary (67 percentage of injected dose, %ID) and renal
(23%ID) excretion within one month post injection. By con-
trast, 3.98%ID of Au is excreted from liver and kidney within
one month after i.v. injection of PEGylated HAuNSs (PEG-
HAuNSs). Comparatively, PEG-HAuNSs are almost nonme-
tabolizable, while PEG-HCuSNPs are considered biodegradable
nanoparticles. PEG-HCuSNPs do not show significant toxicity
by histological or blood chemistry analysis.
However, with further studies, the researchers found that
nanoparticle-mediated photothermal ablation is employed pri-
marily as a local cancer treatment at the primary site. Thus,
it is less effective in controlling metastatic cancer. An ideal
cancer PTT should not only eradicate the treated primary
tumors, but also induce a systemic antitumor immunity, control
metastatic tumors and achieve the goal of long-term tumor
resistance. For this reason, one promising strategy is to combine
photothermal therapy with immunotherapy [76,77]. Laser-
induced tumor cell death, on the other hand, can release tumor
antigens into the surrounding milieu. Concomitantly, im-
munoadjuvants for cancer immunotherapy promote antigen
uptake and presentation by professional antigen-presenting
cells, thus triggering specific antitumor immunity [76]. There-
fore, PTT may act synergistically with immunotherapy to
enhance immune responses, rendering the tumor residues and
metastases more susceptible to immune-mediated killing.
Recently, Lu et al. [78] developed hollow copper sulfide
nanoparticles with photothermal immunotherapy (Fig. 6).They
Fig. 6 – Diagram of HCuSNPs-CpG-mediated photothermal
immunotherapy of both primary treated and distant
untreated tumors. Reproduced with permission from
Reference [78].
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synthesized immunoadjuvants, oligodeoxynucleotides con-
taining cytosine-quanine (CpG) coated hollow copper sulfide
nanoparticles (HCuSNPs-CpG) for “photothermal immuno-
therapy” in a mouse breast cancer model. Success of this
technique relies on photothermally triggered disintegration of
HCuSNPs, allowing the HCuSNPs-CpG conjugates to reas-
semble and transform into chitosan–CpG nanocomplexes.The
chitosan–CpG nanocomplexes increase their tumor retention
and promote CpG uptake by plasmacytoid dendritic cells. The
HCuSNPs-CpG-mediated photothermal immunotherapy elicits
more effective systemic immune responses than immuno-
therapy or PTT alone, resulting in combined anticancer effects
against primary treated as well as distant untreated tumors.
Strong antitumor effectiveness, combined with quick elimi-
nation, would seem to justify further development of this
HCuSNPs conjugate-based photothermal immunotherapy.
Besides aforementioned CuS nanostructures, novel class of
metal chalcogenide as photothermal therapy agent is two-
dimensional (2D) transition-metal dichalcogenides (TMDCs).
For example, MoS2, MoSe2,WSe2 andWS2, all consist of a hex-
agonal layer of metal atoms (M) sandwiched between two layers
of chalcogen atoms (X) within stoichiometry MX2.The common
feature of these materials is the layered structure with strong
covalent bonding within each layer and weak van der Waals
forces between different MX2 sheets. For their special charac-
teristics, TMDCs have become the rising star in recent years,
offering great opportunities in physics, chemistry and mate-
rials science. However, the exploration of this new class of
TMDCs nanomaterials in the area of biomedicine is still at its
infant stage. Currently, Chou et al. demonstrated the possibil-
ity of using as-made MoS2 nanosheets as a new NIR absorbing
agent for in vitro-photothermal-killing of cancer cells for the
first time [79]. Chen and co-workers presented the fabrica-
tion of a two-dimensional MoS2/Bi2S3 composite theranostic
nanosystem for multimodality tumor CT and PA imaging and
photothermal therapy [80]. Li et al. demonstrated in vivo-
photothermal-ablation of tumors by local injection of Bi2Se3
nanosheets directly into tumors [81]. In recent years, Cheng
et al. [82] used the Morrison method to fabricate single-
layered WS2 nanosheets with high-yield. Subsequently, using
the thiol chemistry method, the surface ofWS2 nanosheets is
coated with polyethylene glycol (PEG), which greatly im-
proves the physiological stability and biocompatibility of those
nanosheets (Fig. 7a). It is well-known that X-ray computed to-
mography (CT) imaging is one of the most commonly used
imaging tools for clinic diagnosis and medical research. Based
on a lot of studies, CT contrast agents often absorb and weaken
the incident X-rays to produce tissue contrasts in the diagnostic
Fig. 7 – (a) A scheme showing the exfoliation and PEGylation of WS2 nanosheets. (b) CT images of WS2–PEG solutions with
different concentrations. In vivo dual-model imaging in 4T1-tumor bearing mice. (c) CT images of mice before and after i.t.
injection with WS2–PEG (5 mg/ml, 20 μl). (d) CT images of mice before and after i.v. injection with WS2–PEG (5 mg/ml,
200 μL). The CT contrast was obviously enhanced in the mouse liver (green dashed circle) and tumor (red dashed circle).
(f) Survival curves of mice after various treatments as indicated in (e). Reproduced with permission from Reference [82].
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regime. Thus the attenuation of CT contrast depends on the
interaction between X-ray and the inner shell electrons of atoms
with high atomic numbers. Fig. 7b–d presents the CT images
and Hounsfield unit (HU) values of different concentrations of
WS2–PEG in water, which show a sharp signal enhancement
as the increase of WS2–PEG concentrations. The slope of the
HU value for WS2–PEG is about 22.01 HU L/g, which appeared
to be much higher than that of iopromide (15.9 HU L/g), a com-
mercial iodine-based CT contrast agent used in the clinic.
Utilizing the strong absorbance in the NIR region and strong
X-ray attenuation ability of WS2, Liu et al. successfully dem-
onstrate the in vivo enhanced X-ray CT and photoacoustic
tomography (PAT) bimodal imaging of tumors, respectively. In
animal experiments, after either intratumoral injection with
a low dose of WS2–PEG or intravenous injection with a mod-
erate dose of this nanoagent, realizing 100% of tumor
elimination after NIR laser irradiation at a relatively low power
density (Fig. 7e and f). These works encourage further in-
depth investigations of this novel type of nanomaterials for
biomedical applications.
2.3. Carbon-based nanomaterials (e.g., graphene oxide
and carbon nanotubes)
2.3.1. Graphene oxide
Graphene oxide (GO) is a two-dimensional material obtained
from the oxidative exfoliation of graphite. Graphene and GO
have become one of the most attractive materials for the fol-
lowing reasons: (1) large surface area; (2) lightweight; (3) high
strength and electrical conductivity; (4) the capacity of optical
property-expressing plasmon, fluorescence, and nonlinear emis-
sion. The absorbance of GO extends from the ultraviolet (UV)
wavelength to the NIR region.Thus, the absorbance at 808 nm
was used to express the PTT. This photothermal property of
GO was applied in in vivo photothermal ablation of tumors [83].
However, this GO dispersion was not easily achieved in bio-
applications because of the aggregation that is caused by the
high degree of the binding between GO and proteins or with
other salts in serum.Therefore, the carboxyl groups in the as-
prepared GO were functionalized covalently using amine-
terminated PEG (PEG–GO) to increase the level of dispersion
and decrease cytotoxicity. Robinson et al. [84] developed
nanosized, reduced GO sheets (nano-rGO) (~20 nm in average
lateral dimension) with noncovalent PEGylation (PEG-rGO).The
nano-rGO was aggregated in the solution after reduction due
to the removal of functional groups from the GO sheets. The
increased hydrophobicity of the nano-rGO sheets caused ag-
gregation even with the remaining PEG chains attached to GO
through the reduction. To restore the dispersion, the PEG-
rGO was PEGylated functioned again using sonication with a
polymer (two methoxy-terminated PEG and one C17 chain at-
tached to the poly maleic anhydride) to form polymer coated
PEG-rGO (expressed as polymer-2PEG-rGO).The polymer-2PEG-
rGO regained stability as a homogeneous suspension in buffers
and other biological solutions without aggregation even under
harsh centrifugation conditions. In addition, it is worth noting
that the polymer-2PEG-rGO resulted in a significant ~6.8 fold
increase in the NIR absorption at 808 nm than non-reduced
nano-GO and covalently PEGylation nano-GO.This enhance was
ascribed to the increase of the degree of the π conjugation in
GO after chemical reduction. Subsequently, the high NIR
absorbance of polymer-2PEG-rGO allowed for effective photo-
thermal heating of solutions at a low concentration of polymer-
2PEG-rGO. At a concentration of ~20 mg/L, rapid photothermal
heating occurred upon irradiation of a low power 808 nm laser
at 0.6 W/cm2. Temperatures above the photoablation limit of
50 °C were readily reached within 5min of irradiation.This work
shall lead to systematic in vivo investigations of nano-rGO for
photothermal treatment of tumor models in mice using low
doses of nano-rGO at low laser powers.
To further enhance the photothermal effect of nano-
materials, the plasmon-rich Au nanoparticles [85] and quantum
dots (QDs) [86] were combined with GO. For example, Lim et al.
[85] synthesized reduced GO-coated gold nanoparticles (gold
nanoshells and nanorods) by electrostatic interaction in situ
chemical reduction. The new hybrid material generated well-
defined r-GO-AuNS and r-GO-AuNR. The r-GO as shell and Au
nanoshell/Au nanorod as core existed in the hybrid nano-
structures. The r-GO-AuNS and r-GO-AuNR colloidal solu-
tions exhibit good stability at room temperature, because the
carboxylic acid and hydroxyl groups still exist in incomplete
reduced r-GO. The photothermal performance of r-GO-AuNS
or r-GO-AuNR was studied in dry and solution state under NIR
illumination (808 nm, continuous wave, power density: 3.0 W/
cm2). For the dry state, r-GO-AuNS/r-GO-AuNR led to a 2.9 fold
increase in ΔT upon irradiation compared withAu nanoparticles
and non-reduced GO-AuNS/GO-AuNR. For the solution state,
solutions with the same optical density and sample volume
were illuminated for 5 min at 3.0W/cm2, continuous wave (CW):
808 nm. The heating rates of r-GO-AuNS/r-GO-AuNR solution
were greater than Au nanoparticles and non-reduced
GO-AuNS/GO-AuNR.These independent measurements dem-
onstrate the greater photothermal effect of particles coated with
r-GO, which could be attributable to the interactions between
the r-GO and the gold plasmons. The therapeutic effect of the
photothermal rGO-AuNS/r-GO-AuNR was further demon-
strated on human umbilical vein endothelial cells (HUVECs).
HUVECs were incubated with non-reduced GO- or r-GO-
coated and uncoated Au nanoparticles for 24 h followed by
irradiation (3.0 W/cm2, CW: 808 nm) for 1 min.The cell viability
in r-GO-AuNS and r-GO-AuNR were 23% and 33%, respec-
tively, whereas 41–43% for Au NS or GO-Au NS, and 53–57% for
Au NR and GO-Au NR, respectively. These results showed that
r-GO coating on plasmonic nanoparticles accelerated cell killing.
The main reason for increased killing of cells is that r-GO-Au
nanoparticles showed very powerful phototoxicity for cancer
cells. Showed excellent photothermal properties, which may
be useful in improving biomedical applications based on the
photothermal effect, by increasing their efficacy and/or de-
creasing the duration of therapy.
As we all know, when early studies on GO-assisted cancer
therapeutics, GO was limited to serving as the drug delivery
vehicle, as GO-assisted chemotherapy. Generally, the hexago-
nal arrangement of carbon in GO favors the noncovalent loading
of anticancer drug cargo using π–π stacking. The GO exhibits
a radical increase in drug loading of approximately 200% by
weight, and this is the first drug carrier to achieve over 100%
loading consistently. In addition, the GO was able to unload
the cargo under highly acidic and basic conditions because of
the compromise in the hydrogen bonds between the —COOH
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and the —OH groups of GO, and between the —OH and
the —NH2 groups of DOX [87,88]. Following the studies on the
aforementioned spontaneous release, the photothermal char-
acteristics of GO were subsequently introduced to determine
the combination of PTT and chemotherapy.Wang et al. [89] used
mesoporous silica-coated GO (expressed as GS) to administer
chemotherapy and PTT. In this study, the GO was coated with
mesoporous silica to form a sandwich structure. The GS was
then coated with PEG (expressed as GSP) to achieve solubility
and IL31 peptides for glioma cell targeting (expressed as GSPI).
Finally, GSPI loaded the chemotherapeutic drug DOX, yield-
ing GSPID (Fig. 8a), the photothermal effect of GSPI could
promote the release of DOX.The NIR irradiation apparently en-
hanced the cumulative release of DOX at different time and
pH values due to heat stimulative dissociation of the strong
interactions between DOX and GSPI including π–π stacking and
pore adsorption (Fig. 8b). The result means the photothermal
effect of GSPI could significantly increase the sensitivity of che-
motherapy (Fig. 8c). Regarding the targeting property of IL31
peptides,we confirmed that GSPID exhibited significantly higher
cellular uptake and cytotoxicity in glioma cells, and no appar-
ent effect on normal cells, compared to GSPD. These findings
provided an excellent drug delivery system for combined
therapy of glioma due to the advanced chemo-photothermal
synergistic targeted therapy and good drug release proper-
ties of GSPID, which could effectively avoid frequent and
invasive dosing and improve patient compliance.
2.3.2. Carbon nanotubes
Carbon nanotubes (CNTs) are carbon nanomaterials, includ-
ing both single-walled nanotubes (SWNTs) and multi-walled
nanotubes (MWNTs). The strong optical absorption and high
photon-to-thermal energy conversion efficiency of CNTs in the
NIR region combined with a high-absorption cross-sectionmake
CNTs a suitable candidate for PTT [90,91]. The proper surface
functionalization of CNTs renders them biocompatible and
enables them serve as efficient cancer drug delivery vehicles.
Based on a lot of studies, the loading of aromatic drugs (e.g.
DOX) using CNTs by employing noncovalent π–π stacking is a
simple process. In particular, the surface of the CNTs can be
occupied approximately 70–80% by DOX molecules [92]. Based
on this, Liu et al. [93,94] demonstrated DOX loading, delivery
and chemotherapy using the composite. The SWNTs were
coated with mesoporous silica (MS) to load drug and then
Fig. 8 – (a) Design of GSPID as a multifunctional drug delivery system for combined dhemo-photothermal targeted therapy
of Glioma. (b) Cumulative release profiles of DOX from GSPID at different pH values with 6 W/cm2 NIR irradiation. Data are
expressed as mean ± SEM (n = 3). (c) Cell viability profiles of glioma cells. Reproduced with permission from Reference [89].
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further functionalized with polyethylene glycol (PEG) to acquire
enhanced solubility and stability in physiological environ-
ments, expressed as SWNT@MS-PEG. Interestingly, SWNT@
MS-PEG with drug molecules (DOX), photothermal heating of
the core SWNT under NIR laser would trigger release of drug
molecules (DOX) loaded inside the mesoporous silica shell, re-
sulting in the enhanced cancer cell killing. This enhancement
of therapeutic effect was ascribed so that DOX molecules are
encapsulated insidemesoporous structure of theMS shell.There
was a weaker interaction between DOX and nanotube surface
in the SWNT@MS-PEG/DOX complex. The drug release in the
SWNT-PEG/DOX appears to be less sensitive to temperature,
while in the SWNT@MS-PEG/DOX photothermal heating could
instantly trigger DOX release from pores as also seen in many
other MS coated nanostructures. Next, 4T1 cells were incu-
bated with SWNT@MS-PEG/DOX, SWNT@MS-PEG, and free DOX
for 1 h, followed by irradiation with the 808 nm laser at dif-
ferent power densities for 20 min (Fig. 9a). It was found that
SWNT@MS-PEG/DOX treated cells showed remarkably reduced
viabilities as laser power intensities increase. In comparison,
the free DOX induced cancer cell killing was not significantly
affected by laser irradiation. Photothermal heating induced by
SWNT@MS-PEG without chemotherapy, on the other hand, ap-
peared to be much less effective compared to the combination
therapy, especially under lower laser powers (Fig. 9b). There-
fore, it is concluded that NIR-light triggered intracellular drug
release in such combined photothermal and chemotherapy
could offer an obvious synergistic effect to destruct cancer cells.
In vivo Bald/c mice were developed by cancer 4T1 cells and i.v.
injected with SWNT@MS-PEG/DOX, SWNT@MS-PEG, DOX, and
PBS, respectively. After 24 h, the tumors were irradiated by the
808 nm laser at a moderate power density of 0.5 W/cm2 for
20 min. It was found that the tumor surface temperatures of
mice treated with SWNT@MS-PEG/DOX and SWNT@MS-PEG
were increased and maintained at ~48 °C during laser irradia-
tion. In contrast, the mice treated with PBS and DOX showed
no apparently temperature increase in the tumor region after
being irradiated by the laser. Remarkably, the tumor growths
on mice with injection of SWNT@MS-PEG/DOX were effec-
tively inhibited after NIR laser irradiation as a result of the
combined chemo-photothermal therapy. In addition, SWNTwas
loaded with docetaxel (DTX) using π–π accumulation, and was
subsequently subjected to surfacemodification conducted using
poly-N-vinylpyrrolidone (PVP) and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000]-maleimide [95]. Maleimide was further conjugated with
the targeting NGR peptide (Asn-Gly-Arg) to form NGR-SWNT/
DTX.The NGR-SWNT/DTX was administered intravenously to
the mice bearing S180 tumor xenografts followed by irradia-
tion with an 808 nm laser at a power density of 1.4W/cm2 (NGR-
SWNT/DTX with laser) for 13 days. The tumor volume was
inhibited at the early stages (7th day) of combined chemo-
therapy and PTT. The other groups that were treated by
chemotherapy only (NGR-SWNT/DTX) or PTT only (NGR-
SWNT with laser) exhibited a continual increase in tumor
volume. Further surface engineering of those nanostructures
may allow active tumor targeting and more precisely con-
trolled drug release under other stimuli in addition to NIR light,
to achieve cancer therapy with even better specificity.
The combination of PTT nanomedicine-treatment to-
gether with antibody-based immunotherapy may be a novel
cancer therapeutic strategy, which not only is able to destroy
the primary tumor, but also able to inhibit cancer metastasis
at distant organs in the body [96]. However, whether and how
CNT-based photothermal therapy would trigger any immuno-
logical response and play any effect in inhibiting tumor
metastasis remain largely unknown. Recently,Wang et al. [97]
reported that photothermal ablation of primary tumors with
single-walled carbon nanotubes (SWNTs) in combination with
anti-CTLA-4 antibody therapy is able to prevent the develop-
ment of tumor metastasis in mice. It is found that polymer-
coated SWNTs could not only be used for photothermal tumor
destruction, which releases tumor-associated antigens, but also
can act as an immunological adjuvant to greatly promote matu-
ration of dendritic cells (DCs) and production of anti-tumor
cytokines. The mice bearing subcutaneous 4T1 murine
breast tumors were intratumorally injected with SWNTs
(dose = 0.33 mg/kg). After irradiation with an 808 nm NIR laser
at 0.5W/cm2 for 10min, the tumor temperature jumped to 53 °C,
which is high enough to effectively ablate tumor cells. After
SWNT-induced photothermal treatment, all tumors on mice
Fig. 9 – (a) A scheme showing NIR-triggered drug release
from SWNT@MS-PEG/DOX in vitro. The uncovered DOX
fluorescence from its quenched state inside
SWNT@MS-PEG/DOX could be an indicator of drug release.
(b) Relative viabilities of 4T1 cells after various treatments.
In this experiment, 4T1 cells were incubated with SWNT@
MS-PEG/DOX(L+), SWNT@MS-PEG(L+), SWNT@MS-PEG/DOX,
DOX(L+) and free DOX ([DOX] = 25 μM), for 1 h. Then, the
cells were washed with fresh cell culture and irradiated
with the 808 nm laser at different power densities for
20 min. Afterwards, those cells were re-incubated for
additional 24 h before the MTT assay. P values were
calculated by Tukey’s post-test (***P < 0.001, **P < 0.01, or
*P < 0.05). Reproduced with permission from Reference [95].
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were completely eliminated, without showing a single case of
tumor relapse at their original sites. In addition, both SWNTs
alone and SWNT-based PTT were able to increase the secre-
tion of pro-inflammatory cytokines IL-1β, IL-12p70, IL-6 andTNF-
α. Particularly, the serum level of TNF-α, which plays an
important role in anti-tumor immune responses, was dra-
matically enhanced after SWNT-treated PTT. It is likely that PTT
with CNTs is not just burning of tumors, but also to inhibit
cancer metastasis. Thus, immunological responses triggered
by PTTmay offer clinically valuable therapeutic advantages over
surgery in cancer treatment.
In addition, SWNTs decorated with noble metals were used
to conduct efficient PTT and surface-enhanced Raman spec-
troscopy (SERS) imaging. The DNA-functionalized SWNTs are
modified with noble metal (Ag or Au) nanoparticles via an in
situ solution phase synthesis method comprised of seed at-
tachment, seeded growth, and surface modification with PEG,
yielding SWNT-Ag-PEG and SWNT-Au-PEG nanocomposites
stable in physiological environments [98]. Subsequently, uti-
lizing folic acid (FA) conjugated SWNT-Au-PEG-FA, selective
cancer cell labeling and Raman imaging is realized. Owing to
the strongly enhanced Raman signals of SWNT-Au-PEG-FA, the
cancer cells showed remarkably shortened imaging time com-
pared to that when using a non-enhanced SWNT-nanoprobe
(Fig. 10). Moreover, the SWNT-Au-PEG-FA nanocomposite also
exhibits dramatically improved photothermal cancer cell killing
efficacy.The enhancement is attributable to the strong surface
plasmon resonance absorption by the gold shell grown on the
nanotube surface.The photostability of SWNT-Au-PEG-FA was
compared with that of Au NR by exposing them for 1 h to an
808 nm laser with a power density of 1 W/cm2. Au NR exhib-
ited a complete loss of NIR absorbance, whereas SWNT-Au-
PEG-FA retained nearly 87% of the absorbance intensity.Taking
the intrinsic properties of both SWNTs and gold nanoparticles
together, the SWNT-Au nanocomposite developed here may be
an interesting and promising nano-platform in biosensing,
optical imaging, and phototherapy.
Carbon-based nanomaterials, i.e. graphene oxide and carbon
nanotubes, are fabricated and utilized as a multifunctional plat-
form for chemotherapy and photothermal therapy. Carbon-
based nanomaterials have demonstrated large heating efficiency
and high drug loading amount. However potential clinical imple-
mentations of carbon-based nanomaterials are still hampered
by distinctive barriers such as poor bioavailability and intrin-
sic toxicity, which cause difficulties in tumor targeting and
penetration as well as in improving therapeutic outcome. For
sure, this will be one of the main working areas in the field
of carbon-based nanomaterials during the next years.
3. Conclusions and perspectives
In summary, we have presented a detailed review of the in-
organic nanocomposite materials for PTT. Inorganic
nanocomposites such as gold nanoparticles, palladium
nanoparticles, metal chalcogenide nanoparticles, carbon
nanotubes and graphene oxide have been extensively ex-
plored as photothermal therapy agents (PTA) for cancer therapy.
We summarized for each kind of inorganic PTA, fundamental
light-to-heat conversion property, synthesis method, the ef-
ficiency of in vitro and in vivo thermal therapies, and
multifunctional synergy therapies (already possible by the com-
bination of many different techniques such and PTT, CT, and
PAT). Based on studies reviewed, inorganic PTA-assisted cancer
therapy can effectively induce site-specific cell death in both
in vitro and in vivo treatments. The tremendous development
of nanotechnology brings us closer to the dream of clinical ap-
plication of nanoparticles in photothermal therapies of tumors.
However, the following disadvantages of inorganic PTA are re-
quired to note for the clinical execution of these cancer
therapies in the future:
(1) Photothermal conversion efficiency and stability: Ac-
cording to clinical requirement, the inorganic
nanoparticles with high energy conversion efficiency and
good stability should be synthesized. The studies show
that high photothermal conversion efficiency requires
large absorption cross sections of nanoparticles for optical
wavelengths. This would ensure an efficient absorp-
tion of optical radiation, thus achieving the PTT with low-
power laser sources. For example, the optical-response
band and the photothermal efficiency of Au nanoparticles
can be tuned and improved by exploring plasmon hy-
bridization by the introduction of the dielectric gap in
the form of core–shell structures [99]. In addition, owing
to the presence of sharp tips as well as their high surface-
to-volume ratios, the absorption of branched Au
nanostructures could be more effective in photother-
mal conversion.
Besides high photothermal conversion, good photother-
mal stability also is necessary in PTT application. From the
shapes of the molecules, the anisotropic nanostructures lack
good thermal stability. For example, gold nanorods (GNRs) have
the tendency to transform into nanospheres when exposed to
NIR laser, accompanied with the disappearance of the NIR ab-
sorption band [50].The photothermal stability of GNRs also can
be improved by design of core–shell structures. Thus, it is be-
lieved that the performance of PTA can be further improved
with the reasonable design and synthesis.
(2) Toxicity: Generally, the clearance of PTA and their acute
and long-term toxicity need to be thoroughly examined
Fig. 10 – Schematic illustration of the synthetic procedure
used for the SWNT@Au nanocomposite. Reproduced with
permission from Reference [98].
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before use. In addition, toxicity of PTA should only be
activated in the presence of optical radiation. PTA should
be non-toxic to both healthy cells and cancer cells
without NIR radiation. This is required to achieve a
selective treatment with minimum side effects. Thus,
these nanoparticles should meet the requirement of
the safety, effectiveness, and quality control standards
of new drug development. For GNRs, the cetyltri-
methylammonium bromide (CTAB) used as a surfac-
tant stabilizer during the synthesis process could cause
cytotoxicity and thus needs to be replaced prior to any
in vitro or in vivo application. To overcome the limita-
tion of GNRs in in vivo cancer PTT, PEGylation of GNRs
was attempted to lower the cytotoxicity and the liver
accumulation of GNRs. Additionally, the CNTs were re-
ported to show genotoxicity, as they can pierce the
cells and enter the nucleus easily. CNTs with appropri-
ate surface coatings have been found to be not obviously
toxic to animals and could be gradually excreted from
mice over time [100,101]. Based on aforementioned
studies, to reduce the toxicity of PTA, the surface of
the PTA is often modified by biological molecules (PEG,
FA, GSH, etc.). Thus, it is required to have charge, or
functional groups, or hydrogen bonds, etc. on the surface
of the photothermal materials.
(3) Visual-guided therapies: The unique physicochemical
properties of nanomaterials have offered an opportu-
nity to integrate different theranostic modalities into a
single nanoplatform for combined cancer treatments with
real-time diagnosis. Before these new nanomaterials are
tested in cancer patients, detailed preclinical studies
should be conducted, especially to investigate the phar-
macokinetics, in vivo tumor targeting, and therapeutic
effects of these nanoparticles.The PEGylated PTA of gold
nanoparticles and carbon-based materials have demon-
strated large heating efficiency and outstanding
biocompatibility. However, they have the main draw-
back of showing a weak fluorescence,whichmakes it hard
to track them in real in vivo treatments.This implies the
incorporation of luminescent nanothermometers in the
volume to be treated simultaneously with the photother-
mal agents. Therefore, fluorescence imaging and real-
time control can be realized and adjusted using various
dopants such as quantumdots, organic dye, etc.We believe
that multifunctional nanoparticles will be developed of-
fering heating, tracking and sensing in a single structure
in the near future.
On the basis of the current research, we think that the ul-
timate challenge for cancer treatment is to be able to diagnose
and cure cancer without surgical intervention and avoiding the
occurrence of side effects. New technology should aim to
develop nanomaterials that allow for efficient, specific in vivo
delivery of therapeutic agents without systemic toxicity, and
the dose delivered as well as the therapeutic efficacy can be
accurately monitored non-invasively over time.Therefore, the
research on new inorganic nanomaterials as PTA still is an at-
tractive field that should be highly improved. This will be one
of the main working areas in the field of nanotechnology and
nanomedication in the next years.
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